UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2020
Commission File Number
Kazia Therapeutics Limited
(Translation of registrants name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☑
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited (Registrant)
Kate Hill
Kate Hill
Company Secretary
Date 17 December 2020
Appendix 3Y
Change of Directors Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Directors Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASXs property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Kazia Therapeutics Limited (Kazia) |
ABN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Steven Coffey | |
Date of last notice | 10 November 2020 |
Part 1 - Change of directors relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a director should be disclosed in this part.
Direct or indirect interest
|
Indirect | |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Fortune 501 Pty Limited (S R Coffey Superfund)
Steven Coffey | |
Date of change
|
16 & 17 December 2020 | |
No. of securities held prior to change
|
402,500 shares (indirect)
400,000 unlisted options (direct)
| |
Class
|
Ordinary shares | |
Number acquired
|
8,500 ordinary shares (indirect)
8,015 shares (direct)
| |
Number disposed
|
+ See chapter 19 for defined terms. | ||
01/01/2011 Appendix 3Y Page 1 |
Appendix 3Y
Change of Directors Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
|
8,500 ordinary shares at an average price of $1.24 per share
8,015 ordinary shares at $1.225 per share
| |
No. of securities held after change | 411,000 ordinary shares (indirect) 8,015 ordinary shares (direct)
400,000 unlisted options (direct)
| |
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back
|
Purchased on market |
Part 2 Change of directors interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be disclosed in this part.
Detail of contract
|
||
Nature of interest
|
||
Name of registered holder (if issued securities)
|
||
Date of change
|
+ See chapter 19 for defined terms. | ||
Appendix 3Y Page 2 |
01/01/2011 |
Appendix 3Y
Change of Directors Interest Notice
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
||
Interest acquired
|
||
Interest disposed
|
||
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
|
||
Interest after change
|
Part 3 +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
If prior written clearance was provided, on what date was this provided? |
+ See chapter 19 for defined terms. | ||
01/01/2011 Appendix 3Y Page 3 |